Market news

CARLSBAD, Calif., September 08, 2026--AlloSCOPE 5D Patent Release

Lineage Cell Therapeutics is rated Hold due to its reliance on out-licensing and a risk-adjusted fair value below the current share price. Click for more.

Detailed price information for Lineage Cell Therapeutics Inc (LCTX-A) from The Globe and Mail including charting and trades.

Lineage Cell Therapeutics Inc (LCTX) reports net income of $1.5 million, extends cash runway into Q3 2028, and advances key pipeline programs despite revenue decline.

Detailed price information for Arm Holdings Plc ADR (ARM-Q) from The Globe and Mail including charting and trades.

CARLSBAD, Calif., August 06, 2026--Q2 2026 Earnings Release

CARLSBAD, Calif., July 30, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off the shelf", cell therapies for serious medical conditions, today announced that it will report its second quarter 2026 financial and operating results on August 6, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on August 6, 2026, at 4:30 p.m. Eastern Time

Tipranks Press Release.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease. Chief Executive Officer Brian Culle